Tempest Therapeutics’ (TPST) “Buy” Rating Reiterated at HC Wainwright

Tempest Therapeutics (NASDAQ:TPST)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $47.00 price objective on the stock.

A number of other equities analysts have also recently weighed in on TPST. Scotiabank started coverage on Tempest Therapeutics in a report on Thursday, March 14th. They set a “sector outperform” rating and a $13.00 price target for the company. William Blair reissued an “outperform” rating on shares of Tempest Therapeutics in a research report on Wednesday, March 20th.

Tempest Therapeutics Trading Down 24.9 %

NASDAQ TPST traded down $0.71 on Thursday, reaching $2.14. 27,045,410 shares of the company were exchanged, compared to its average volume of 976,543. The business’s fifty day moving average price is $3.31 and its 200 day moving average price is $3.71. The stock has a market capitalization of $47.55 million, a P/E ratio of -1.24 and a beta of -1.78. The company has a current ratio of 3.13, a quick ratio of 3.13 and a debt-to-equity ratio of 0.20. Tempest Therapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $9.77.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.08. Analysts forecast that Tempest Therapeutics will post -1.58 earnings per share for the current year.

Hedge Funds Weigh In On Tempest Therapeutics

A hedge fund recently bought a new stake in Tempest Therapeutics stock. MayTech Global Investments LLC bought a new stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 10,000 shares of the company’s stock, valued at approximately $44,000. Tempest Therapeutics makes up approximately 0.0% of MayTech Global Investments LLC’s portfolio, making the stock its 29th biggest holding. MayTech Global Investments LLC owned approximately 0.05% of Tempest Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.